Germany’s medical cannabis program is facing an unusual challenge: it worked too well. Since the nation reclassified cannabis from a narcotic to a non-narcotic medical treatment, prescriptions have skyrocketed, prices have tumbled, and product options have multiplied, leaving policymakers scrambling to keep up.
Data from December 2025 shows medical cannabis prescriptions up more than 3,300% compared with early 2024, the last month before the regulatory change. This surge is not a fleeting spike; prescription numbers remained exceptionally high throughout 2025, fueled by streamlined access and the introduction of telemedical consultations.
Alongside soaring demand, prices fell dramatically. The average cost per gram of medical cannabis flower dropped from €8.33 in January 2025 to €5.23 by year’s end. Meanwhile, the number of available cannabis flower products expanded from 468 to 724, with most options priced below €6 per gram. Patients now spend as little as €30–€50 per month on legal, supervised treatments.
Despite public fears of “misuse,” clinical evidence tells a different story. A review using established medical criteria found no increase in problematic use, hospitalizations, or mental health issues. The rising prescription numbers reflect legitimate demand, not abuse.
Experts warn that restricting telemedical access or tightening regulations could backfire. Limiting digital pathways would likely push patients back to unlicensed, potentially unsafe sources. Simplified prescriptions and digital healthcare platforms have instead enabled cost-effective, regulated care, bringing patients under medical supervision rather than leaving them to self-medicate.
Germany’s experiment illustrates a modern healthcare paradox: when a system succeeds, the success itself can create political headaches. For patients, however, the outcome is simple—more access, lower prices, and safer care.
Dabbin-Dad Newsroom
Too Much of a Good Thing: Germany’s Cannabis Boom Breaks the System
If you liked this post, say thanks by sharing it
